Douglas Sato

Summary

Affiliation: Tohoku University
Country: Japan

Publications

  1. doi request reprint Aquaporin-4 antibody-positive cases beyond current diagnostic criteria for NMO spectrum disorders
    Douglas Kazutoshi Sato
    Department of Neurology, Tohoku University School of Medicine, Sendai, Japan
    Neurology 80:2210-6. 2013
  2. ncbi request reprint Neutralizing antibodies are associated with a reduction of interferon-β efficacy during the treatment of Japanese multiple sclerosis patients
    Douglas Kazutoshi Sato
    Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan
    Tohoku J Exp Med 228:85-92. 2012
  3. ncbi request reprint Treatment of neuromyelitis optica: an evidence based review
    Douglas Sato
    Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan
    Arq Neuropsiquiatr 70:59-66. 2012
  4. ncbi request reprint Atypical presentations of neuromyelitis optica
    Douglas Sato
    Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan
    Arq Neuropsiquiatr 69:824-8. 2011

Detail Information

Publications4

  1. doi request reprint Aquaporin-4 antibody-positive cases beyond current diagnostic criteria for NMO spectrum disorders
    Douglas Kazutoshi Sato
    Department of Neurology, Tohoku University School of Medicine, Sendai, Japan
    Neurology 80:2210-6. 2013
    ..To analyze aquaporin-4 (AQP4) antibody-positive patients who do not fulfill the current diagnostic criteria of neuromyelitis optica (NMO) and NMO spectrum disorders (NMOSD)...
  2. ncbi request reprint Neutralizing antibodies are associated with a reduction of interferon-β efficacy during the treatment of Japanese multiple sclerosis patients
    Douglas Kazutoshi Sato
    Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan
    Tohoku J Exp Med 228:85-92. 2012
    ..Therefore, routine NAbs testing is recommended also in Asian populations to ensure the early identification of patients who would benefit from a change in therapy...
  3. ncbi request reprint Treatment of neuromyelitis optica: an evidence based review
    Douglas Sato
    Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan
    Arq Neuropsiquiatr 70:59-66. 2012
    ..However, there is no controlled randomized trial to confirm the safety and efficacy for the drugs currently used in NMO...
  4. ncbi request reprint Atypical presentations of neuromyelitis optica
    Douglas Sato
    Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan
    Arq Neuropsiquiatr 69:824-8. 2011
    ..The prompt identification of NMO patients with atypical presentations may benefit these patients with institution of early treatment to reduce disability and prevent further attacks...